
Quarterly report 2025-Q3
added 11-14-2025
Utah Medical Products Financial Ratios 2011-2025 | UTMD
Annual Financial Ratios Utah Medical Products
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
57.7 | 74.2 | 79.5 | 89.6 | 25.5 | 18.8 | 40.2 | 19.1 | 18.0 | 18.8 | 17.7 | 14.9 | 14.7 |
P/S |
20.1 | 24.9 | 25.4 | 25.5 | 8.0 | 8.3 | 8.3 | 5.9 | 5.3 | 5.2 | 5.0 | 3.6 | 2.9 |
EPS |
4.6 | 4.5 | 4.0 | 3.0 | 4.0 | 5.0 | 2.3 | 3.2 | 3.2 | 3.0 | 3.1 | 2.8 | 2.0 |
EV (Enterprise Value) |
162 M | 272 M | 276 M | 263 M | 342 M | 308 M | 316 M | 213 M | 199 M | 211 M | 207 M | 168 M | 138 M |
EBITDA per Share |
4.79 | 5.61 | 5.35 | 3.93 | 6.56 | 5.82 | 5.86 | 5.05 | 4.98 | 5.18 | 4.78 | 4.97 | 4.02 |
EV/EBITDA |
14.1 | 12.7 | 13.6 | 13.7 | 13.9 | 10.8 | 10.1 | 10.2 | 10.9 | 8.4 | 8.5 | ||
PEG |
-278.23 | 28.68 | 16.49 | -41.82 | -1.21 | 0.16 | -1.39 | 7.51 | 4.33 | -81.17 | 1.72 | 0.43 | 0.65 |
P/B |
1.9 | 3.0 | 3.1 | 3.0 | 3.7 | 3.9 | 4.4 | 3.4 | 3.1 | 3.3 | 3.3 | 3.0 | 2.7 |
P/CF |
11.1 | 16.0 | 15.5 | 15.2 | -83.8 | 21.2 | 22.3 | 20.7 | 15.7 | 15.0 | 16.8 | 11.4 | 9.8 |
ROE % |
3.34 | 3.99 | 3.86 | 3.32 | 14.57 | 20.85 | 10.89 | 17.51 | 17.00 | 17.63 | 18.83 | 19.95 | 18.19 |
ROA % |
3.16 | 3.68 | 3.57 | 3.05 | 13.41 | 18.60 | 9.17 | 15.84 | 14.96 | 14.03 | 14.13 | 13.22 | 9.71 |
ROCE % |
13.08 | 17.32 | 17.62 | 13.33 | 16.58 | 19.78 | 21.74 | 22.00 | 20.84 | 22.47 | 20.28 | 21.99 | 17.74 |
Current Ratio |
19.0 | 12.9 | 13.6 | 12.5 | 15.9 | 11.6 | 9.3 | 11.5 | 8.1 | 3.3 | 3.2 | 2.4 | 1.8 |
DSO |
132.1 | 143.4 | 130.5 | 134.4 | 36.9 | 34.4 | 31.9 | 29.8 | 41.5 | 41.6 | 39.1 | 38.1 | 45.6 |
DIO |
166.3 | 140.0 | 129.0 | 144.1 | 144.7 | 125.9 | 127.4 | 106.2 | 95.9 | 109.1 | 105.8 | 97.8 | 118.2 |
DPO |
18.0 | 18.0 | 15.6 | 20.7 | 23.0 | 22.7 | 22.7 | 21.2 | 14.8 | 20.8 | 17.4 | 22.5 | 21.8 |
Operating Cycle |
298.4 | 283.5 | 259.5 | 278.6 | 181.6 | 160.3 | 159.4 | 136.0 | 137.4 | 150.7 | 144.9 | 135.9 | 163.8 |
Cash Conversion Cycle |
280.5 | 265.5 | 243.9 | 257.9 | 158.6 | 137.6 | 136.7 | 114.9 | 122.5 | 129.9 | 127.5 | 113.5 | 142.0 |
All numbers in USD currency
Quarterly Financial Ratios Utah Medical Products
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.82 | 0.94 | 0.92 | - | 1.02 | 0.98 | 1.09 | - | 1.08 | 1.16 | 1.16 | - | 1.18 | 1.13 | 0.97 | - | 1.15 | 0.94 | 0.83 | - | 0.81 | 0.36 | 0.85 | - | 1 | 0.95 | 0.84 | - | 1.81 | 1.15 | 1.1 | - | 0.97 | 1.04 | 0.95 | - | 0.78 | 0.87 | 0.86 | - | 0.81 | 0.78 | 0.71 | - | 0.75 | 0.76 | 0.73 | - | 0.69 | 0.71 | 0.74 | - | 0.74 | 0.65 | 0.76 | - | 0.62 | 0.55 | 0.37 |
EBITDA per Share |
- | - | 1.01 | - | - | - | 1.12 | - | - | - | 1.27 | - | 1.54 | 1.47 | 1.28 | - | 1.53 | 1.4 | 1.11 | - | 1.12 | 0.63 | 1.09 | - | 1.32 | 1.3 | 1.15 | - | 1.33 | 1.46 | 1.39 | - | 1.39 | 1.44 | 1.32 | - | 1.17 | 1.23 | 1.19 | - | 1.19 | 1.14 | 1.07 | - | 1.2 | 1.17 | 1.07 | - | 1.1 | 1.08 | 1.09 | - | 1.21 | 1.06 | 1.35 | - | 1.12 | 0.99 | 0.67 |
ROE % |
10.29 | 10.93 | 11.12 | 8.75 | 11.93 | 12.24 | 12.91 | 10.20 | 14.16 | 14.93 | 15.30 | 11.01 | 14.87 | 14.74 | 14.11 | 13.75 | 13.22 | 12.25 | 10.33 | 10.50 | 11.50 | 12.31 | 14.52 | 14.57 | 14.07 | 18.00 | 19.36 | 20.85 | 13.81 | 10.85 | 10.96 | 10.89 | 18.36 | 17.96 | 17.71 | 13.59 | 17.97 | 18.10 | 17.59 | 12.39 | 16.77 | 16.76 | 16.96 | 12.98 | 17.22 | 17.09 | 17.05 | 13.10 | 18.44 | 19.54 | 19.90 | 15.52 | 21.01 | 21.16 | 21.31 | 13.63 | 5.49 | 4.86 | 3.28 |
ROA % |
9.91 | 10.50 | 10.63 | 5.40 | 8.40 | 8.65 | 9.22 | 9.52 | 13.13 | 13.75 | 14.06 | 10.10 | 13.67 | 13.57 | 12.97 | 12.66 | 12.14 | 11.26 | 9.50 | 9.66 | 10.58 | 11.33 | 13.37 | 13.42 | 12.85 | 16.25 | 17.36 | 18.60 | 12.48 | 9.61 | 9.46 | 9.17 | 15.72 | 15.65 | 15.73 | 12.29 | 16.14 | 16.15 | 15.58 | 10.90 | 14.38 | 14.02 | 13.83 | 10.33 | 13.52 | 13.22 | 12.99 | 9.84 | 13.37 | 13.72 | 13.58 | 10.28 | 13.21 | 12.60 | 12.08 | 7.27 | 2.93 | 2.59 | 1.75 |
ROCE % |
10.31 | 10.80 | 10.85 | 8.50 | 11.71 | 12.23 | 13.09 | 10.60 | 15.36 | 16.90 | 17.97 | 13.60 | 18.24 | 18.12 | 17.85 | 12.78 | 16.27 | 15.12 | 12.61 | 9.17 | 13.49 | 14.33 | 16.84 | 12.81 | 17.76 | 18.38 | 19.63 | 16.21 | 22.20 | 23.25 | 24.01 | 18.48 | 24.17 | 23.87 | 23.66 | 18.15 | 23.89 | 23.95 | 23.41 | 17.01 | 23.20 | 23.66 | 24.26 | 18.44 | 24.49 | 24.34 | 24.18 | 18.60 | 26.37 | 28.09 | 28.93 | 22.81 | 31.49 | 32.41 | 33.37 | 21.91 | 8.68 | 7.93 | 5.29 |
Current Ratio |
32.8 | 37.0 | 22.4 | 24.0 | 23.6 | 21.7 | - | 19.0 | 17.4 | 15.0 | 13.1 | 12.9 | 11.6 | 13.4 | 11.3 | 13.6 | 12.2 | 12.4 | 12.0 | 12.5 | 12.5 | 12.5 | 12.5 | 12.6 | 12.6 | 12.6 | 12.6 | 9.3 | 9.3 | 9.3 | 9.3 | 6.3 | 6.3 | 6.3 | 6.3 | 11.0 | 10.4 | 10.4 | 10.4 | 8.3 | 8.3 | 8.3 | 8.3 | 4.9 | 4.9 | 4.9 | 4.9 | 4.0 | 4.0 | 4.0 | 4.0 | 3.0 | 3.0 | 3.0 | 3.0 | 2.1 | 2.1 | 2.1 | 2.1 |
DSO |
34.2 | 34.7 | 37.8 | - | 33.7 | - | - | - | 25.9 | 26.3 | 34.1 | - | 38.6 | 36.2 | 40.2 | 35.3 | 34.3 | 31.7 | 34.4 | 31.2 | 35.7 | 42.6 | 37.0 | 36.6 | 34.6 | 36.5 | 37.0 | 37.0 | 34.7 | 32.9 | 31.8 | 32.4 | 32.6 | 30.5 | 30.4 | - | 30.4 | 27.9 | 34.4 | - | 41.9 | 40.0 | 41.3 | - | 40.0 | 40.9 | 42.0 | - | 39.4 | 39.5 | 38.2 | - | 37.8 | 39.5 | 37.0 | - | 40.1 | 41.6 | - |
DIO |
177.3 | 176.7 | 190.9 | - | 197.2 | - | - | - | 175.8 | 178.5 | 182.9 | - | 149.7 | 127.1 | 133.0 | - | 125.9 | 114.5 | 138.5 | - | 142.6 | 148.0 | 147.4 | - | 123.3 | 145.2 | 159.3 | - | 120.6 | 124.0 | 122.6 | - | 131.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
16.3 | 17.3 | 17.6 | - | 19.9 | - | - | - | 16.4 | 21.0 | 21.9 | - | 20.2 | 19.6 | 21.1 | - | 22.4 | 19.2 | 18.5 | - | 18.1 | 18.7 | 21.2 | - | 19.6 | 23.1 | 23.9 | - | 21.7 | 22.4 | 22.0 | - | 23.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
211.5 | 211.5 | 228.7 | - | 230.9 | - | - | - | 201.7 | 204.8 | 217.0 | - | 188.3 | 163.3 | 173.2 | 35.3 | 160.2 | 146.2 | 172.9 | 31.2 | 178.3 | 190.6 | 184.4 | 36.6 | 158.0 | 181.7 | 196.3 | 37.0 | 155.3 | 157.0 | 154.4 | 32.4 | 164.5 | 30.5 | 30.4 | - | 30.4 | 27.9 | 34.4 | - | 41.9 | 40.0 | 41.3 | - | 40.0 | 40.9 | 42.0 | - | 39.4 | 39.5 | 38.2 | - | 37.8 | 39.5 | 37.0 | - | 40.1 | 41.6 | - |
Cash Conversion Cycle |
195.2 | 194.2 | 211.1 | - | 211.0 | - | - | - | 185.3 | 183.8 | 195.1 | - | 168.2 | 143.7 | 152.1 | 35.3 | 137.8 | 127.0 | 154.4 | 31.2 | 160.3 | 171.8 | 163.3 | 36.6 | 138.4 | 158.6 | 172.4 | 37.0 | 133.6 | 134.6 | 132.4 | 32.4 | 141.0 | 30.5 | 30.4 | - | 30.4 | 27.9 | 34.4 | - | 41.9 | 40.0 | 41.3 | - | 40.0 | 40.9 | 42.0 | - | 39.4 | 39.5 | 38.2 | - | 37.8 | 39.5 | 37.0 | - | 40.1 | 41.6 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Utah Medical Products, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
BioLife Solutions
BLFS
|
$ 24.51 | 0.49 % | $ 1.13 B | ||
|
Baxter International
BAX
|
$ 19.45 | 1.57 % | $ 9.92 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 200.24 | -0.32 % | $ 57.6 B | ||
|
Harvard Bioscience
HBIO
|
$ 0.72 | -3.0 % | $ 30.5 M | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
ICU Medical
ICUI
|
$ 147.83 | -0.41 % | $ 3.61 B | ||
|
iRhythm Technologies
IRTC
|
$ 170.06 | 0.73 % | $ 5.31 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Repro Med Systems
KRMD
|
$ 5.73 | -0.87 % | $ 261 M | ||
|
LeMaitre Vascular
LMAT
|
$ 84.3 | 0.35 % | $ 1.89 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 4.64 | -0.64 % | $ 93.5 M | ||
|
Masimo Corporation
MASI
|
$ 137.72 | -0.45 % | $ 7.34 B | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Merit Medical Systems
MMSI
|
$ 86.66 | -0.05 % | $ 5.05 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
OraSure Technologies
OSUR
|
$ 2.51 | 0.6 % | $ 187 M | ||
|
Alcon
ALC
|
$ 79.51 | 0.9 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
$ 41.55 | -1.96 % | $ 1.95 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
electroCore
ECOR
|
$ 4.82 | 1.47 % | $ 26.6 K | ||
|
ResMed
RMD
|
$ 252.92 | 0.26 % | $ 36.9 B | ||
|
AngioDynamics
ANGO
|
$ 13.39 | 1.9 % | $ 547 M | ||
|
The Cooper Companies
COO
|
$ 81.06 | -1.24 % | $ 16.1 B | ||
|
STAAR Surgical Company
STAA
|
$ 23.98 | -0.62 % | $ 1.18 B | ||
|
STERIS plc
STE
|
$ 253.49 | 0.68 % | $ 25 B | ||
|
Glaukos Corporation
GKOS
|
$ 112.17 | 3.02 % | $ 5.43 B | ||
|
Haemonetics Corporation
HAE
|
$ 80.33 | -3.78 % | $ 4.04 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.01 | -2.49 % | $ 186 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
$ 557.08 | 2.72 % | $ 198 B | ||
|
Microbot Medical
MBOT
|
$ 2.28 | -5.39 % | $ 23.3 M | ||
|
Milestone Scientific
MLSS
|
$ 0.36 | -6.38 % | $ 28.7 M | ||
|
Nephros
NEPH
|
$ 4.82 | -3.98 % | $ 50.1 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
$ 22.05 | 0.36 % | $ 3.8 B | ||
|
Pro-Dex
PDEX
|
$ 43.41 | 0.07 % | $ 143 M | ||
|
Pulse Biosciences
PLSE
|
$ 14.45 | 1.44 % | $ 694 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 32.4 M | ||
|
Stereotaxis
STXS
|
$ 2.38 | 0.63 % | $ 192 M | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.45 | -1.04 % | $ 2.33 B | ||
|
Repligen Corporation
RGEN
|
$ 159.03 | 1.04 % | $ 8.86 M | ||
|
Retractable Technologies
RVP
|
$ 0.83 | 0.17 % | $ 24.8 M | ||
|
Teleflex Incorporated
TFX
|
$ 126.56 | -0.09 % | $ 5.93 B | ||
|
West Pharmaceutical Services
WST
|
$ 269.2 | 0.62 % | $ 19.7 B |